HeartFlow's RoadMap Analysis on display at ACC.23 in New Orleans.
The California-based company, fresh off receiving expanded Medicare coverage and a new Category I CPT code for its AI offerings, will have a significant presence at TCT 2024.
The news comes just days after CMS confirmed these technologies would start receiving expanded Medicare coverage in November. HeartFlow and other AI vendors have already shared their excitement over the decision.
The U.S. Food and Drug Administration has its hands full making sure medical AI products are safe, efficacious and trustworthy before they hit the market. The rise of ever-more-innovative iterations of the technology—not least generative AI—is only adding to the burden.
Massachusetts Institute of Technology won a $50,000 award to help commercialize its 3D printed, polymeric auxetic stent to treat pediatric aortic coarctation. It is bioresorbable so the patient can continue to grow without the need for as many reinterventions.
Most cardiac devices do not fit young children, making it especially important for growth in pediatric cardiology to continue. The FDA helped fund a contest aimed at identifying new devices that show a ton of potential.
iCardio.ai, co-founded by a cardiologist, is part of the Cedars-Sinai Accelerator program. The startup has already announced new partnerships with Viz.ai, Abbott and others in the cardiac health space.
